45results about How to "Improve neurological symptoms" patented technology

The present invention provides new sequences, gene constructions, vectors and pharmaceutical compositions for the treatment of diseases and specially, for the treatment of mucopolysaccharidoses.

A Chinese medicine for treating senile dementia, dizziness, disturbed sleep, etc is prepared from fleece flower root, lotus leaf, cistanche, earthworm and uniflower swisscentaury root through respective extracting, and proportional mixing.

The medicine for treating cardiac and cerebral vascular diseases is prepared with astragalus root and notoginseng as material, and is Chinese medicine injection, including injection liquid, transfusion liquid and freeze dried powder for injection, prepared through extraction, purification and addition of proper amount of medicinal supplementary material. The medicine has high stability and long effective period, and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic test shows that the medicine can protect brain against oxygen lack and cardiac muscle damage, raise anaerobic resistance, lower serum LDH and CK activity and reduce myocardial infarction range. The medicine is used in treating cardiac and cerebral vascular diseases and has fast acting, determined curative effect and no toxic side effect.

The invention discloses a small molecule polypeptide and an application thereof in preparing a medicine for preventing and treating ischemic stroke. By synthesizing a TAT protein transduction domain,the protein polypeptide of CDK5 and the fusion protein TAT-CDK5-CTM of the autophagy targeted motif CTM can be combined and inhibited, the TAT is used to carry the CDK5 protein polypeptide, which is transported by blood through a blood cerebral barrier, and is taken up by neurons. The peptide is applied to in-vitro and in-vivo ischemic stroke models to effectively block the bonding effect of the NR2B subunit of a N-methyl aspartate receptor (NMDAR) and the cyclin-dependent protein kinase 5 (CDK5), the CTM mediates the polypeptide molecules which are bonded with CDK5 protein to enter lysosomalfor degradation, neuronal apoptosis and necrosis induced by CDK5 downstream can be inhibited, brain damage after ischemic stroke can be reduced, and the application provides a molecular target for thedevelopment of drugs for the treatment of ischemic stroke.

The present invention relates to a series of medicine combinations for remedying diabetic chronic complication and a preparation method thereof, which are compound oral preparations (comprising troche, dispersible tablet, effervescent tablet, capsule preparation, soft capsule and granule preparation) which are mainly made from at least two active components of mecobalamin, cobamamide, vitamin B12, epalrestat, lipoic acid and calcium dobesilate and pharmic acceptable auxiliary materials. The preferential combinations of the present invention are the mecobalamin plus the lipoic acid, the mecobalamin and the lipoic acid plus the calcium dobesilate, the mecobalamin and the epalrestat plus the calcium dobesilate, the mecobalamin, the lipoic acid and the epalrestat plus the calcium dobesilate, and the mecobalamin and the vitamin B12 plus cobamamide. The present invention is mainly used for remedying the nervous lesion of the diabetic chronic complication.

The invention relates to a composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia, belongs to the field of medicine health, and provides a composition capable of alleviating asthenopia. The active components of the composition comprise fish eyeball tissues or an extract thereof, fish eye socket tissues and an extract thereof, the theanine and the gamma-aminobutyric acid. Test results in crowds prove that the composition has effect on eye local symptoms of asthenopia, can obviously improve the neurosis symptoms caused by asthenopia of different degrees, such as unconcentrated attention, and reduced memory, is notable in effect of alleviating asthenopia and has broad market development prospect.

The invention relates to medical composition containing lipoic acid and mecobalamin and a preparation method and application thereof. The medical composition is formed by taking the lipoic acid and mecobalamin as medical active components and blending with pharmaceutically acceptable auxiliary materials; the medical composition can be used for the treatment of abnormal feeling caused by peripheral neuropathy of diabetes. The invention adopts the lipoic acid and mecobalamin as materials and adds auxiliary materials with some special kinds and proportions to prepare and develop diversified oral preparations such as tablets, capsules, granules, dispersible tablets, orally disintegrating tablets, buccal tablets, dry suspensions, pills drops, soft capsules, effervescent tablets and effervescent granules as well as preparations used for intravenous injection such as injections and freezing dried powder according to the technical method of the invention.

The invention relates to an edaravone sodium chloride injection liquid and a preparation method thereof. 100 ml of the injection liquid comprises 20-40 mg of edaravone, 0.6-1.0 g of sodium chloride, 100-150 mg of propylene glycol, 2.5-3.5 g of vitamin C, and 0.3-1.0 g of sodium hydrogen carbonate, wherein the pH is adjusted to 3.5-5.0. The preparation process of the injection liquid comprises thesteps: liquid preparation, filtration, filling, capping, sterilization and lamp inspection; liquid preparation adopts a two-step preparation method, and the preparation process adopts low temperaturepreparation. The adopted method is simple to operate and low in cost, and the prepared edaravone sodium chloride injection liquid has good drug stability and fewer side effects, can effectively reducethe generation of impurities, has high patient compliance with medication and safety, can be used for improving neurological symptoms, daily living activities and function disorder caused by acute cerebral infarction, and can effectively prevent and treat brain injury.

The invention provides an application of sodium valproate to preparation of a medicine for restraining formation of glial scars. The structural formula of the sodium valproate is as shown in the description. Through experiment, the inventor finds that the sodium valproate has remarkable cranial nerve protecting effects, and can effectively restrain activation of primary astroglia cells and notablyrestrain the formation of the glial scars after the brain tissue of mice is damaged, so that the encephalatrophy volume of mice suffering from local cerebral ischemia can be obviously improved, the neurological symptoms of the mice can be notably improved, and restoration can be promoted; and the above situation indicates that the sodium valproate has important application value in preparation ofthe medicine for restraining the formation of the glial scars.

The invention relates to a composition containing fish eyes, theanine and phosphatidylserine for relieving visual fatigue, and belongs to the field of medicines and health. The invention provides a composition for relieving visual fatigue. The active ingredients of the composition comprise fish eyeball tissue or an extract thereof, fish eye socket tissue or an extract thereof, theanine and phosphatidylserine. The trial results of crowds show that the composition disclosed by the invention not only aims at the local symptoms of eyes having visual fatigue, but also can significantly improve neuropsychological syndromes caused by different degrees of visual fatigue, such as inattention, memory deterioration, and the composition is notable in the effect of relieving the visual fatigue, and hasbroad market prospects.

The invention relates to a composition containing fructus lycii, flos chrysanthemi and gamma-aminobutyric acid for relieving asthenopia, and belongs to the field of medical health. The invention provides a composition for relieving asthenopia, the active ingredients of which comprise fructus lycii, flos chrysanthemi and gamma-aminobutyric acid. The results of the crowd trial show that the composition of the invention not only aims at the eye local symptoms of asthenopia, but also can significantly improve the mental and neurological symptoms caused by varying degrees of asthenopia, such as inattention and decreased memory, has a significant effect in relieving asthenopia, and has a wide range of market prospect.

The invention discloses application of 5-(3', 5'-dimethoxybenzylidene)-2-sulfo-imidazole-4-one to preparation of drugs for treating cerebrovascular diseases. According to relevant researches disclosed by the invention, the compound has a remarkable cerebral nerve protection effect, can obviously reduce the volume of cerebral infarction of a focal cerebral ischemia rat and can obviously improve neurological signs; and moreover, the protection effect of an IV4 compound to cerebral ischemic injuries is related to the inhibition of the activation of lysosomal enzyme cathepsin B, so that the compound can be used for preparing drugs for preventing or treating diseases such as ischemic brain injuries, cerebral hemorrhage, cerebral thrombosis, cerebral embolism, cerebral infarction, cerebral stroke, lacunar infarction, transient ischemia attacks, cerebral arteriosclerosis and diabetic cardiovascular complications.

The invention provides application of a compound SB216763 to preparing cerebrovascular disease preventing and/or treating drugs and a pharmaceutical composition of the compound SB216763. The compoundSB216763 is 3-(2, 4-dichlorophenyl)-4-(1-methyl-1H-indole-3-yl)-1H-pyrrole-2, 5-diketone with a structural formula shown in the description. Experiments discover that the compound SB216763 can achievesignificant cerebral nerve protecting effects, significantly reduce the volume of acute cerebral infarction of rats with focal cerebral ischemia and improve the nerve symptoms of the rats. The drugsprepared with the compound SB216763 can be applied to preventing or treating diseases such as ischemic brain injury, cerebral thrombosis, cerebral embolism, cerebral infarction, cerebral apoplexy, lacunar infarction, transient cerebral ischemia, cerebral arteriosclerosis and diabetic cerebrovascular complications.

The present invention provides the medical use of paeoniflorin in the manufacture of medicaments for treating and preventing apoplexy, Parkinson's diseases and other nervous system diseases.

The present invention belongs to the field of health-care products and particularly relates to an alcoholism-preventing and liver-protecting agent containing chicory nutrient components and a preparation method thereof. The alcoholism-preventing and liver-protecting agent is prepared from chicory oligopeptide, chicory coumarin, a traditional Chinese medicinal extract, honey and deionized water according to a certain ratio; the chicory oligopeptide and chicory coumarin are extracted from chicory roots; the chicory oligopeptide is rich in amino acids of alanine, leucine, etc., can promote production of coenzyme NAD+ of ethanol dehydrogenase, is beneficial to catabolism of ethanol in body, inhibits rise of the ethanol in blood, and achieves an alcoholism-preventing purpose; the chicory coumarin can accelerate cell repair and has obvious protective effects on liver cells; and the traditional Chinese medicinal extract is prepared by extracting pueraria lobata flowers, pueraria lobata roots,pseudo-ginseng, silybum marianum, chrysanthemum, raisin tree seeds and nutmegs. By combing the active ingredients, the alcoholism-preventing and liver-protecting agent inhibits gastrointestinal absorption of alcohol, accelerates metabolism of the ethanol, reduces damage of the ethanol to the liver cells, and can play significant roles in preventing alcoholism and protecting the liver.

The invention relates to a composition containing fructus lycii, flos chrysanthemi, phosphatidylserine and theanine for relieving visual fatigue, and belongs to the field of medicine and health. The invention provides the composition for relieving visual fatigue, which is prepared from the active ingredients: the fructus lycii, the flos chrysanthemi, the phosphatidylserine and the theanine. The test result shows that the composition provided by the invention not only aims at visual fatigue eye local symptoms but also can remarkably improve psychosomatic manifestations such as inattention and memory deterioration caused by different degrees of visual fatigue, the composition has a remarkable effect on relieving visual fatigue, and has a broad market prospect.

The invention relates to a theanine, phosphatidylserine and anthocyanin containing composition for relieving visual fatigue, and belongs to the field of medicine health. The composition for relievingvisual fatigue provided by the invention consists theanine, phosphatidylserine and anthocyanin as active ingredients. When tried by people, results indicate that the composition provided by the invention can relieve local symptoms of eyes having the visual fatigue, and moreover, the composition can obviously such psychoneural symptoms caused by visual fatigue of different degrees such as low concentration, memory loss and the like; and the composition is obvious in effect of relieving the visual fatigue and has a broad market prospect.

The invention discloses an application of liquiritin in preparation of a medicine for treating or preventing enterovirus 71 infection and an application of liquiritin in preparation of a medicine for inhibiting enterovirus 71 replication, and belongs to the technical field of traditional Chinese medicine pharmacy. Research finds that after the liquiritin is adopted for intragastric administration, the expression quantity of EV71VP1 in brain tissue can be reduced, the inflammatory factor IL-6 can be reduced, and virus replication is inhibited, so that the neurological symptom of the hand-foot-and-mouth disease caused by EV71 is improved.